Among these, baricitinib was originally identified using artificial intelligence as a suitable candidate for COVID-19 treatment, due to its ability to bind with high affinity to some key regulators of clathrin-mediated endocytosis, namely AP2-associated protein kinase-1 (AAK1) and possibly cyclic G-associated kinase (GAK), thus inhibiting the entry of SARS-CoV-2 into cells and the intracellular assembly of virus particles (100). This evidence concerns the gene AAK1 and COVID-19.